Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications

P. Russo; M. Valenti; G. Cimoli; S. Parodi; G. L. Mariani; M. Venturini; P. F. Conte

doi:10.1016/S0959-8049(05)80307-7

Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications

P. Russo, M. Valenti, G. Cimoli, S. Parodi, G. L. Mariani, M. Venturini, P. F. Conte

Research output: Contribution to journal › Article › peer-review

Abstract

Synergism between recombinant human tumour necrosis factor (rHuTNF) and DNA topoisomerase II inhibitor VP16 during the killing of cells has been studied in six human ovarian cancer cell lines (A2774, A2780, SW626, IGROV-1, SKOV3, Pa1) and a cervical carcinoma cell line (Me180). Studies were performed using an assay of colony formation inhibition (drug treatment for 1 h) and a growth inhibition assay (continuous exposure for 20 h). Concomitant treatment of cells with VP16+rHuTNF enhanced cell killing in all the cell lines tested-an effect observed in both short- and long-term cytotoxicity assays. This study suggests that the activity of VP16 in ovarian cancer cell lines might be enhanced by rHuTNF in in vitro models.

Original language	English
Pages (from-to)	1157-1161
Number of pages	5
Journal	European Journal of Cancer
Volume	29
Issue number	8
DOIs	https://doi.org/10.1016/S0959-8049(05)80307-7
Publication status	Published - 1993

ASJC Scopus subject areas

Cancer Research
Oncology
Hematology

Access to Document

10.1016/S0959-8049(05)80307-7

Fingerprint Dive into the research topics of 'Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications'. Together they form a unique fingerprint.

Cite this

Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications. / Russo, P.; Valenti, M.; Cimoli, G.; Parodi, S.; Mariani, G. L.; Venturini, M.; Conte, P. F.

In: European Journal of Cancer, Vol. 29, No. 8, 1993, p. 1157-1161.

Research output: Contribution to journal › Article › peer-review

@article{51618a36936047dead4030591ab0df6e,

title = "Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications",

abstract = "Synergism between recombinant human tumour necrosis factor (rHuTNF) and DNA topoisomerase II inhibitor VP16 during the killing of cells has been studied in six human ovarian cancer cell lines (A2774, A2780, SW626, IGROV-1, SKOV3, Pa1) and a cervical carcinoma cell line (Me180). Studies were performed using an assay of colony formation inhibition (drug treatment for 1 h) and a growth inhibition assay (continuous exposure for 20 h). Concomitant treatment of cells with VP16+rHuTNF enhanced cell killing in all the cell lines tested-an effect observed in both short- and long-term cytotoxicity assays. This study suggests that the activity of VP16 in ovarian cancer cell lines might be enhanced by rHuTNF in in vitro models.",

author = "P. Russo and M. Valenti and G. Cimoli and S. Parodi and Mariani, {G. L.} and M. Venturini and Conte, {P. F.}",

year = "1993",

doi = "10.1016/S0959-8049(05)80307-7",

language = "English",

volume = "29",

pages = "1157--1161",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

number = "8",

}

TY - JOUR

T1 - Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications

AU - Russo, P.

AU - Valenti, M.

AU - Cimoli, G.

AU - Parodi, S.

AU - Mariani, G. L.

AU - Venturini, M.

AU - Conte, P. F.

PY - 1993

Y1 - 1993

N2 - Synergism between recombinant human tumour necrosis factor (rHuTNF) and DNA topoisomerase II inhibitor VP16 during the killing of cells has been studied in six human ovarian cancer cell lines (A2774, A2780, SW626, IGROV-1, SKOV3, Pa1) and a cervical carcinoma cell line (Me180). Studies were performed using an assay of colony formation inhibition (drug treatment for 1 h) and a growth inhibition assay (continuous exposure for 20 h). Concomitant treatment of cells with VP16+rHuTNF enhanced cell killing in all the cell lines tested-an effect observed in both short- and long-term cytotoxicity assays. This study suggests that the activity of VP16 in ovarian cancer cell lines might be enhanced by rHuTNF in in vitro models.

AB - Synergism between recombinant human tumour necrosis factor (rHuTNF) and DNA topoisomerase II inhibitor VP16 during the killing of cells has been studied in six human ovarian cancer cell lines (A2774, A2780, SW626, IGROV-1, SKOV3, Pa1) and a cervical carcinoma cell line (Me180). Studies were performed using an assay of colony formation inhibition (drug treatment for 1 h) and a growth inhibition assay (continuous exposure for 20 h). Concomitant treatment of cells with VP16+rHuTNF enhanced cell killing in all the cell lines tested-an effect observed in both short- and long-term cytotoxicity assays. This study suggests that the activity of VP16 in ovarian cancer cell lines might be enhanced by rHuTNF in in vitro models.

UR - http://www.scopus.com/inward/record.url?scp=0027273992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027273992&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(05)80307-7

DO - 10.1016/S0959-8049(05)80307-7

M3 - Article

C2 - 8518027

AN - SCOPUS:0027273992

VL - 29

SP - 1157

EP - 1161

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 8

ER -